论文部分内容阅读
目的探讨和比较紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗卵巢癌的疗效。方法选取2012年5月至2015年5月间收治的60例卵巢癌患者,按照随机数字表法分为研究组和对照组,每组30例。研究组患者采用紫杉醇脂质体联合卡铂治疗,对照组患者采用紫杉醇联合卡铂治疗,比较两组的疗效及不良反应。结果研究组患者的总有效率为73.3%(22/30),对照组为70.0%(21/30),差异无统计学意义(P>0.05)。研究组患者的过敏反应、白细胞减少、血红蛋白减少、血小板减少、皮疹、肌痛、胃肠道反应发生率均显著低于对照组,差异有统计学意义(P<0.05),但两组患者的脱发发生率差异无统计学意义(P>0.05)。结论紫杉醇脂质体联合卡铂治疗卵巢癌与紫杉醇联合卡铂治疗卵巢癌疗效相当,但不良反应少。
Objective To investigate and compare the efficacy of paclitaxel liposome combined with carboplatin and paclitaxel combined with carboplatin in the treatment of ovarian cancer. Methods Sixty ovarian cancer patients who were admitted between May 2012 and May 2015 were divided into study group and control group according to the random number table method, with 30 cases in each group. Patients in the study group were treated with paclitaxel liposomes combined with carboplatin, and patients in the control group were treated with paclitaxel combined with carboplatin. The curative effect and adverse reactions of the two groups were compared. Results The total effective rate was 73.3% (22/30) in the study group and 70.0% (21/30) in the control group, with no significant difference (P> 0.05). The incidence of anaphylaxis, leukopenia, hemoglobin, thrombocytopenia, rash, myalgia and gastrointestinal reaction in the study group were significantly lower than those in the control group (P <0.05), but the patients in both groups The incidence of hair loss was no significant difference (P> 0.05). Conclusion paclitaxel liposomes combined with carboplatin in the treatment of ovarian cancer and paclitaxel combined with carboplatin in the treatment of ovarian cancer with similar efficacy, but less adverse reactions.